# Quincy Chu

Source: https://onco.cc/people/quincy-chu/  
OnCo record `quincy-chu` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Edmonton oncologist who was lead author of KEYNOTE-483 (CCTG IND.227), the trial that showed adding pembrolizumab to chemotherapy lengthens survival in pleural mesothelioma.

## Summary

Quincy Chu is a medical oncologist at the Cross Cancer Institute in Edmonton and a thoracic disease site leader in the Canadian Cancer Trials Group. He was first author of the 2023 Lancet report of IND.227/KEYNOTE-483, the international phase 3 trial in which pembrolizumab plus platinum-pemetrexed chemotherapy improved overall survival compared with chemotherapy alone in untreated unresectable pleural mesothelioma, leading to the combination's approval.

## Fields

- Kind: Person
- Last checked: 2026-09-18
- Tags: mesothelioma; immunotherapy; trialist
- Role: Medical oncologist, Cross Cancer Institute and University of Alberta, Edmonton
- Specialisms: Mesothelioma; Lung cancer; Canadian Cancer Trials Group studies

## Connected records

- cancers: [Pleural mesothelioma](https://onco.cc/cancers/pleural-mesothelioma/)
- institutions: [Cancer Care Alberta (Alberta Health Services)](https://onco.cc/institutions/cancer-care-alberta/)
- key papers: [KEYNOTE-483 (CCTG IND.227): pembrolizumab plus chemotherapy versus chemotherapy in untreated pleural mesothelioma](https://onco.cc/key-papers/paper-keynote-483-lancet-2023/)

---
JSON: https://onco.cc/api/v1/entities/quincy-chu.json